Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto11Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba Children&#39;s Hospital, Chiba, Japan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Murakami M, Tomiita M, Nishimoto N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/1e49f8547c624bd8ba503e8ab47ec06d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1e49f8547c624bd8ba503e8ab47ec06d
record_format	dspace
spelling	oai:doaj.org-article:1e49f8547c624bd8ba503e8ab47ec06d2021-12-02T03:51:07ZTocilizumab in the treatment of systemic juvenile idiopathic arthritis1179-156Xhttps://doaj.org/article/1e49f8547c624bd8ba503e8ab47ec06d2012-07-01T00:00:00Zhttp://www.dovepress.com/tocilizumab-in-the-treatment-of-systemic-juvenile-idiopathic-arthritis-a10313https://doaj.org/toc/1179-156XMiho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto11Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba Children&#39;s Hospital, Chiba, JapanAbstract: Systemic juvenile idiopathic arthritis is one of the common rheumatic diseases in childhood and characterized by spiking fever, evanescent skin rash, lymphadenopathy, hepatosplenomegaly, and serositis, in addition to arthritis. Children with systemic juvenile idiopathic arthritis often show growth retardation and developmental abnormality, as well as macrophage activation syndrome, a life-threatening complication. Overproduction of interleukin-6 is pathologically responsible for the systemic inflammatory manifestations and abnormal laboratory results with systemic juvenile idiopathic arthritis. Thus, tocilizumab, a humanized antihuman interleukin-6 receptor antibody, has been developed as a therapeutic agent for the disease. A series of clinical studies have demonstrated the excellent efficacy and safety of tocilizumab for patients with active disease. Tocilizumab was approved for systemic juvenile idiopathic arthritis in Japan in 2008 and in the European Union and the United States in 2011.Keywords: systemic juvenile idiopathic arthritis, tocilizumab, antihuman interleukin-6 receptor antibody, biologicsMurakami MTomiita MNishimoto NDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2012, Iss default, Pp 71-79 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Murakami M Tomiita M Nishimoto N Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
description	Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto11Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba Children&#39;s Hospital, Chiba, JapanAbstract: Systemic juvenile idiopathic arthritis is one of the common rheumatic diseases in childhood and characterized by spiking fever, evanescent skin rash, lymphadenopathy, hepatosplenomegaly, and serositis, in addition to arthritis. Children with systemic juvenile idiopathic arthritis often show growth retardation and developmental abnormality, as well as macrophage activation syndrome, a life-threatening complication. Overproduction of interleukin-6 is pathologically responsible for the systemic inflammatory manifestations and abnormal laboratory results with systemic juvenile idiopathic arthritis. Thus, tocilizumab, a humanized antihuman interleukin-6 receptor antibody, has been developed as a therapeutic agent for the disease. A series of clinical studies have demonstrated the excellent efficacy and safety of tocilizumab for patients with active disease. Tocilizumab was approved for systemic juvenile idiopathic arthritis in Japan in 2008 and in the European Union and the United States in 2011.Keywords: systemic juvenile idiopathic arthritis, tocilizumab, antihuman interleukin-6 receptor antibody, biologics
format	article
author	Murakami M Tomiita M Nishimoto N
author_facet	Murakami M Tomiita M Nishimoto N
author_sort	Murakami M
title	Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
title_short	Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
title_full	Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
title_fullStr	Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
title_full_unstemmed	Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
title_sort	tocilizumab in the treatment of systemic juvenile idiopathic arthritis
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/1e49f8547c624bd8ba503e8ab47ec06d
work_keys_str_mv	AT murakamim tocilizumabinthetreatmentofsystemicjuvenileidiopathicarthritis AT tomiitam tocilizumabinthetreatmentofsystemicjuvenileidiopathicarthritis AT nishimoton tocilizumabinthetreatmentofsystemicjuvenileidiopathicarthritis
_version_	1718401594481967104

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

Ejemplares similares